Edition:
United States

Lannett Company Inc (LCI.N)

LCI.N on New York Stock Exchange

15.65USD
18 Aug 2017
Change (% chg)

$0.55 (+3.64%)
Prev Close
$15.10
Open
$15.00
Day's High
$15.75
Day's Low
$15.00
Volume
94,507
Avg. Vol
117,791
52-wk High
$39.95
52-wk Low
$14.95

LCI.N

Chart for LCI.N

About

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June... (more)

Overall

Beta: 2.82
Market Cap(Mil.): $582.66
Shares Outstanding(Mil.): 37.23
Dividend: --
Yield (%): --

Financials

  LCI.N Industry Sector
P/E (TTM): -- 31.45 32.56
EPS (TTM): -0.09 -- --
ROI: -0.18 15.33 14.89
ROE: -0.50 16.35 16.13

BRIEF-Lannett Co says expects Q4 2017 GAAP EPS $0.12 - $0.15

* Lannett announces preliminary fiscal 2017 fourth-quarter and full-year financial results, comments on fiscal 2018 outlook

Aug 08 2017

BRIEF-Lannett receives approval for Cyproheptadine Hydrochloride Syrup, 2 mg/5 mL

* Lannett receives approval for cyproheptadine hydrochloride syrup, 2 mg/5 ml

Jul 14 2017

BRIEF-Lannett receives approval for additional dosage strengths of hydrocodone bitartrate and acetaminophen tablets usp

* Lannett receives approval for additional dosage strengths of hydrocodone bitartrate and acetaminophen tablets usp

Jun 26 2017

BRIEF-Lannett gets approval for hydrocodone bitartrate, acetaminophen tablets

* Lannett receives approval for hydrocodone bitartrate and acetaminophen tablets USP, 5 mg/300 mg, 7.5 mg/300 mg and 10 mg/300 mg

Jun 22 2017

BRIEF-Lannett names Patrick Lepore to board of directors

* Lannett Company Inc - addition of Lepore will increase total number of directors to seven Source text for Eikon: Further company coverage:

Jun 20 2017

BRIEF-Lannett gets approval for niacin extended-release tablets USP, 500 mg, 1000 mg

* Lannett receives approval for niacin extended-release tablets USP, 500 mg and 1000 mg

Jun 19 2017

BRIEF-Lannett announces approval for amantadine hydrochloride capsules USP, 100 mg

* Lannett announces approval for amantadine hydrochloride capsules USP, 100 mg

Jun 16 2017

BRIEF-Lannett announces FDA approval for levocetirizine dihydrochloride oral solution, 2.5 mg/5 ml

* Lannett announces approval for levocetirizine dihydrochloride oral solution, 2.5 mg/5 ml (0.5 mg/ml)

May 16 2017

BRIEF-Lannett Company Inc files for potential mixed shelf size not disclosed

* Lannett Company Inc files for potential mixed shelf; size not disclosed - sec filing Source text (http://bit.ly/2raUzkw) Further company coverage:

May 12 2017

BRIEF-Lannett voluntarily pays down remaining $25 mln principal balance of revolving credit facility

* Lannett voluntarily pays down remaining $25 million principal balance of revolving credit facility

May 09 2017

Competitors

  Price Chg
AbbVie Inc (ABBV.N) $69.96 +0.11
Pfizer Limited (PFIZ.NS) Rs1,783.00 -10.20
Dr.Reddy's Laboratories Ltd (REDY.NS) Rs1,939.10 -42.90

Earnings vs. Estimates